G-Quadruplex Modulation of TDP-43 Aggregation and Toxicity
2026-05-14
Oldani et al. demonstrate that RNA G-quadruplexes regulate the condensation, intracellular distribution, and cytotoxicity of TDP-43, a protein central to neurodegeneration. Their work highlights the therapeutic potential of stabilizing G-quadruplex structures to mitigate TDP-43-related toxicity, with implications for ALS and related diseases.
CA-074 Me: Precision Cathepsin B Inhibition for Translationa
2026-05-13
This article delivers a thought-leadership perspective on leveraging CA-074 Me, a potent and selective cathepsin B inhibitor, in dissecting necroptosis and lysosomal membrane permeabilization. By weaving recent mechanistic breakthroughs with practical strategic guidance, it empowers translational researchers to advance apoptosis assays, inflammation models, and disease pathway elucidation beyond conventional approaches.
Evaluating Pesticide Drift: UAV vs. Knapsack Sprayer with Rh
2026-05-13
This study provides the first direct, field-scale comparison of pesticide spray drift from unmanned aerial vehicles (UAVs) and electric knapsack sprayers (EKS) using Rhodamine B as a quantitative fluorescent tracer. Results demonstrate that UAVs produce significantly greater drift distances and deposition rates, providing essential data for environmental risk assessment and regulatory decisions in modern agriculture.
S63845 MCL1 Inhibitor: Data-Driven Solutions for Apoptosis A
2026-05-12
This article delivers actionable, scenario-based guidance for optimizing cell viability and apoptosis assays using S63845 MCL1 inhibitor (SKU A8737). By addressing practical questions from experimental compatibility to data interpretation, we highlight validated protocols and performance parameters to support reproducible research. Discover how S63845 enables mitochondrial apoptotic pathway activation and reliable cytotoxicity studies in hematological and solid tumor models.
Calpain Inhibitor I, ALLN: Technical Guidance for Research U
2026-05-12
Calpain Inhibitor I, ALLN (SKU A2602) is a potent, selective inhibitor designed to block calpain and cathepsin activity in apoptosis and inflammation research. It addresses common challenges in protease-driven assays by offering high solubility in organic solvents and minimal off-target toxicity. This reagent is not suitable for diagnostic or clinical applications.
Plant Nanovesicles Alleviate Testicular Injury via Sertoli C
2026-05-11
This study demonstrates that plant-derived exosome-like nanovesicles from Cistanche deserticola can mitigate cyclophosphamide-induced testicular injury by targeting Sertoli cell cycle arrest. The work highlights miR159b-3p’s suppression of P21 as a key mechanism and suggests new avenues for protecting male fertility during chemotherapy.
Novel HER2 Inhibitors Target EMT to Suppress Breast Cancer M
2026-05-11
The referenced study presents the synthesis and biological evaluation of new small-molecule HER2 inhibitors targeting breast cancer through modulation of the epithelial-mesenchymal transition (EMT) pathway. By using Mubritinib as a lead compound, the researchers developed analogs that show improved potency, with implications for both mechanistic cancer biology research and future therapeutic design.
Methyl-β-cyclodextrin: Technical Guidance for Membrane Resea
2026-05-10
Methyl-β-cyclodextrin is a high-purity reagent for extracting cholesterol and modulating lipid organization in cellular membranes, supporting studies of membrane fluidity and cholesterol-dependent signaling. It is not appropriate for diagnostic or therapeutic use, and its efficacy relies on proper storage and workflow practices.
α-Amanitin in Transcriptional Regulation: Applied Workflows
2026-05-09
α-Amanitin empowers researchers to dissect RNA polymerase II-driven transcription with unparalleled specificity, enabling advanced gene expression pathway analysis and oocyte developmental studies. This guide translates recent chromatin reorganization breakthroughs and practical assay workflows into actionable protocols, maximizing reproducibility and data clarity.
Biotin-tyramide: Redefining Proximity Labeling for Translati
2026-05-09
This article explores the mechanistic power and translational impact of Biotin-tyramide, spotlighting its role in enzyme-mediated signal amplification for advanced spatial proteomics and proximity labeling. Leveraging recent findings on RAB GTPase interactomes, we provide strategic, evidence-driven guidance for researchers aiming to unlock new biological insights with precision and reproducibility.
Secreted METTL9 Methyltransferase Restricts Candida in the G
2026-05-08
Bao et al. identify secreted METTL9 as a cross-kingdom antifungal defense mechanism in the intestinal epithelium. By methylating the fungal zincophore PRA1, METTL9 limits Candida albicans colonization and dissemination, suggesting new avenues for antifungal research beyond conventional drug approaches.
Sulfo-Cy3 Azide in Neurodevelopment: Quantitative Fluorescen
2026-05-07
Explore how Sulfo-Cy3 azide, a premier bioconjugation reagent, enables high-fidelity Click Chemistry fluorescent labeling for quantitative neurodevelopmental mapping. Discover advanced assay design, protocol parameters, and unique insights from recent claustrum research.
NADH in Mitochondrial Electron Transport Chain Research
2026-05-07
Leverage reduced nicotinamide adenine dinucleotide (NADH) for advanced mitochondrial electron transport chain research and disease modeling. Discover protocol enhancements, troubleshooting insights, and the latest high-throughput screening innovations that set APExBIO's NADH apart for precise metabolic and redox studies.
Catalpol Inhibits Liver Fibrosis via EphA2/FAK/Src and Glyco
2026-05-06
The referenced study demonstrates that catalpol effectively ameliorates hepatic fibrosis by directly inhibiting aerobic glycolysis in hepatic stellate cells through the EphA2/FAK/Src signaling axis. This mechanistic insight advances the understanding of metabolic reprogramming in liver fibrosis and clarifies potential molecular targets for anti-fibrotic therapy.
Oral Gepotidacin for Gonorrhoea: Phase 3 Non-Inferiority Out
2026-05-06
The EAGLE-1 phase 3 trial demonstrates that oral gepotidacin is non-inferior to standard dual therapy for uncomplicated urogenital gonorrhoea, offering a novel oral treatment option. These findings have significant implications for antimicrobial stewardship and the development of alternative regimens amid rising resistance.
508 records 22/34 page Previous Next First page 上5页 2122232425 下5页 Last page